KLVFF Functionalized Graphene Oxide for Aβ 42 Peptide Electrical Detection: A Promising Nanomaterial for the Development of Alzheimer's Disease Diagnostic Devices
Source abstract
Abstract
Abstract Alzheimer's disease (AD) is a neurodegenerative disorder with a high negative impact in terms of cost and social issues. New kinds of noninvasive, reliable, easy‐to‐use, and cheap biosensors are highly desired. In this work, the use of graphene oxide (GO) sheets functionalized with the peg 4 ‐KLVFF peptide conjugate is reported as a sensing layer for the detection of Aβ 42 protein, a key AD biomarker. An optimized synthetic protocol provides a suitable GO/peptide‐functionalized layer without extensively modifying the planar structure of GO. The nature of the bonds involved in the functionalization process is highlighted through Fourier Transform Infrared Spectroscopy (FTIR) and X‐ray photoelectron spectroscopy (XPS) analyses. The covalently functionalized material (GO@peg 4 ‐KLVFF) is deposited by dielectrophoresis (DEP) between two metal electrodes, forming the sensitive layer. The devices show a selective and linear electrical response as a function of Aβ 42 concentrations. The selectivity toward Aβ 42 is validated using two different scrambled sequences of the amyloid‐β peptides (Aβ 42s , Aβ 40s ) as well as the Tau 26–44 peptide. The different electrical behaviors are discussed in detail and explained by simulating, at the molecular level, the interaction of the different Aβ peptides with GO and KLVFF. Potential chemical interactions are explored, including charge transfer between the peptides and GO.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Cholinesterase and Neurodegenerative Diseases · Electrochemical sensors and biosensors
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Consiglio Nazionale delle Ricerche ‐ Istituto per la Microelettronica e Microsistemi (CNR‐IMM) Ottava Strada n.5 Catania 95121 Italy
Consiglio Nazionale delle Ricerche ‐ Istituto di Cristallografia (CNR‐IC) Via Paolo Gaifami n.18 Catania 95126 Italy
References (59)
Show source-provided references
1. M.Prince A.Wimo G. M.Guerchet G.‐C.Ali Y.‐T.Wu M.Prina World Alzheimer. Report 2015: The Global Impact of Dementia: An Analysis of Prevalence Incidence Cost and TrendsFirst ed. Alzheimer's Disease International London UK2015.
2. 10.1016/j.cell.2012.02.04010.1016/j.cell.2012.02.040 ↗
3. 10.1016/S1474-4422(19)30024-910.1016/S1474-4422(19)30024-9 ↗
4. 10.1007/s00401-014-1371-210.1007/s00401-014-1371-2 ↗
5. 10.1016/j.jalz.2019.03.00910.1016/j.jalz.2019.03.009 ↗
6. 10.1038/nrneurol.2017.11110.1038/nrneurol.2017.111 ↗
7. 10.1016/j.talanta.2019.12064410.1016/j.talanta.2019.120644 ↗
8. 10.1016/j.nantod.2009.06.00310.1016/j.nantod.2009.06.003 ↗
9. Chen C. · Analyst · 2020 · 145 · 336
10. 10.1042/EBC2015000810.1042/EBC20150008 ↗
11. 10.3390/bios1109033610.3390/bios11090336 ↗
12. 10.1016/S1474-4422(17)30159-X10.1016/S1474-4422(17)30159-X ↗
13. 10.1021/acs.nanolett.0c0004810.1021/acs.nanolett.0c00048 ↗
14. 10.3389/fnagi.2018.0013810.3389/fnagi.2018.00138 ↗
15. 10.1093/brain/awy34710.1093/brain/awy347 ↗
16. 10.1038/nrd217610.1038/nrd2176 ↗
17. 10.1074/jbc.271.15.854510.1074/jbc.271.15.8545 ↗
18. 10.1074/jbc.272.19.1260110.1074/jbc.272.19.12601 ↗
19. 10.1002/psc.322710.1002/psc.3227 ↗
20. 10.1016/j.cbpa.2021.05.01110.1016/j.cbpa.2021.05.011 ↗
21. 10.1042/BCJ2020029010.1042/BCJ20200290 ↗
22. 10.1002/cbic.20240043110.1002/cbic.202400431 ↗
23. 10.1016/j.biochi.2017.12.01510.1016/j.biochi.2017.12.015 ↗
24. 10.1016/j.ijbiomac.2022.06.12910.1016/j.ijbiomac.2022.06.129 ↗
25. 10.1007/s00604-020-04267-x10.1007/s00604-020-04267-x ↗
26. 10.1021/acs.analchem.7b0468610.1021/acs.analchem.7b04686 ↗
27. 10.1016/j.carbon.2020.02.06510.1016/j.carbon.2020.02.065 ↗
28. Artemenko A. · Mat. Sci. Eng. · 2021 · 1050
29. 10.1021/la00052a01510.1021/la00052a015 ↗
30. 10.1039/C8CP07632D10.1039/C8CP07632D ↗
31. 10.1039/C5RA18540H10.1039/C5RA18540H ↗
32. 10.1039/D0NJ01906B10.1039/D0NJ01906B ↗
33. 10.1039/c1cc15043j10.1039/c1cc15043j ↗
34. 10.3390/s2223956110.3390/s22239561 ↗
35. 10.1016/j.jcis.2022.01.05110.1016/j.jcis.2022.01.051 ↗
36. 10.1016/j.bios.2021.11329410.1016/j.bios.2021.113294 ↗
37. 10.1016/j.bios.2020.11250510.1016/j.bios.2020.112505 ↗
38. 10.3390/ijms2002029910.3390/ijms20020299 ↗
39. 10.3390/ijms2409840810.3390/ijms24098408 ↗
40. 10.3233/JAD-15096210.3233/JAD-150962 ↗
41. 10.18632/oncotarget.1737110.18632/oncotarget.17371 ↗
42. 10.1038/nsmb.299110.1038/nsmb.2991 ↗
43. 10.3389/fncel.2015.0029710.3389/fncel.2015.00297 ↗
44. 10.1038/s43587-023-00403-310.1038/s43587-023-00403-3 ↗
45. Batatia I. · Adv. Neur. Infor. Proc. Syst. · 2022 · 35
46. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗
47. 10.1046/j.1432-1033.2002.03271.x10.1046/j.1432-1033.2002.03271.x ↗
48. 10.3390/ph1408073210.3390/ph14080732 ↗
49. 10.1016/j.snb.2018.12.12910.1016/j.snb.2018.12.129 ↗
50. 10.1016/j.apsusc.2017.09.11310.1016/j.apsusc.2017.09.113 ↗
51. 10.1016/j.ica.2017.09.06110.1016/j.ica.2017.09.061 ↗
52. 10.1021/acschemneuro.2c0072010.1021/acschemneuro.2c00720 ↗
53. 10.1016/j.sbsr.2015.11.01110.1016/j.sbsr.2015.11.011 ↗
54. 10.1063/1.498188810.1063/1.4981888 ↗
55. 10.3390/nano908109910.3390/nano9081099 ↗
56. 10.3390/nano1301021510.3390/nano13010215 ↗
57. 10.1021/acsanm.4c0486410.1021/acsanm.4c04864 ↗
58. 10.1088/0957-4484/27/24/24570410.1088/0957-4484/27/24/245704 ↗
59. 10.1021/acsphyschemau.3c0002110.1021/acsphyschemau.3c00021 ↗